Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT8 | Q9H7Z6 | 15/20 | 0.74 |
| ▸ | KAT6A | Q92794 | 10/20 | 0.74 |
| ▸ | KAT7 | O95251 | 7/20 | 0.74 |
| ▸ | KAT5 | Q92993 | 10/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25953054 | 0.85 | KAT8 (1.00) | KAT8KAT6AKAT7KAT5 | |
| SCHEMBL25953093 | 0.84 | KAT8 (1.00) | KAT8KAT6AKAT7KAT5 | |
| SCHEMBL25946920 | 0.84 | KAT8 (0.90) | KAT8KAT6AKAT5 | |
| SCHEMBL20232861 | 0.83 | KAT5 (0.68) | KAT8KAT6AKAT7KAT5 | |
| SCHEMBL25946954 | 0.83 | KAT5 (0.75) | KAT8KAT6AKAT7KAT5 | |
| SCHEMBL25948609 | 0.82 | KAT8 (1.00) | KAT8KAT6AKAT7KAT5 | |
| SCHEMBL25946932 | 0.82 | KAT5 (1.00) | KAT8KAT6AKAT7KAT5 | |
| SCHEMBL20233055 | 0.82 | KAT5 (0.71) | KAT8KAT6AKAT7KAT5 | |
| SCHEMBL25946989 | 0.80 | KAT6A (1.00) | KAT8KAT6AKAT7KAT5 | |
| SCHEMBL25947462 | 0.79 | KAT8 (1.00) | KAT8KAT6AKAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | Epizyme, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | Epizyme, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | KAT8 6/4885KAT6A 3/4885KAT7 7/4885 |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | EP300, KAT2A, KAT6A | KAT8 6/4885KAT6A 3/4885KAT7 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.